| Challenges in funding diabetes care: a health economic perspective. | |
| | |
MedLine Citation:
|
PMID: 20950068 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Diabetes mellitus - especially Type 2 diabetes - represents a major threat to public health in nearly all countries worldwide. The number of patients with diabetes is expected to rise to over 438 million by the year 2030. As healthcare resources are considered limited, there is a need for prioritization among the different, existing therapeutic options available for treating or preventing diseases in a given healthcare system. This article will highlight five particular challenges for evaluating complex therapeutic approaches in diabetes care, introducing the health economic fundamentals of cost-effectiveness assessment and the different concepts to determine a cost-effectiveness threshold, with a special focus on the situation in low- and middle-income countries. |
| | |
Authors:
|
Christian Weber |
Related Documents
:
|
17318768 - Medical costs of diabetic complications total costs and excess costs by age and type of... 17108558 - Simulation based cost-benefit analysis of a telemedical system for closed-loop insulin ... 20725588 - Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with m... 10547338 - Stochastic designs in event-related fmri. 8884008 - Hyperbaric oxygen therapy and piracetam decrease the early extension of deep partial-th... 10844618 - Effect of insulin and heparin on glucose-induced vascular damage in cell culture. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of pharmacoeconomics & outcomes research Volume: 10 ISSN: 1744-8379 ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-18 Completed Date: 2011-01-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132257 Medline TA: Expert Rev Pharmacoecon Outcomes Res Country: England |
Other Details:
|
Languages: eng Pagination: 517-24 Citation Subset: IM |
Affiliation:
|
Ernst Basler & Partner Inc., CH-8702 Zollikon, Switzerland. christian.weber@ebp.ch |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost of Illness* Cost-Benefit Analysis Developing Countries Diabetes Mellitus, Type 1 / economics*, epidemiology, therapy Diabetes Mellitus, Type 2 / economics*, epidemiology, therapy Humans Technology Assessment, Biomedical / organization & administration |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Assessing quality of life in the eating disorders: the HeRQoLED-S.
Next Document: Economic evaluation guidelines in Latin America: a current snapshot.